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This article is dedicated to the memory of my 
brother Raymond John Vinters (1952-2020). 
 
 
Beginnings in Canada 
My family were Latvians who, by the end of 
World War II, had become refugees from the Soviet 
Union. For the repressive Communist regime that 
controlled the USSR, my family (on both sides) 
were or would soon become ‘criminals’ who owned 
land and were involved in commerce. They saw no 
future under a Communist regime, and the fate of 
relatives who remained in Latvia after World War II 
confirmed the wisdom of their decision and choice 
– some were exiled to Siberia for many years, oth-
ers simply had their property confiscated. My fami-
ly – grandparents, their two children (one my fa-
ther) and assorted household staff who joined 
them – fled the country as the Red Army moved in 
to ‘liberate’ its people and begin a brutal and mer-
ciless tyranny that would last until the early 1990s. 
During that happy time in the early 1990s the USSR 
thankfully collapsed under the weight of grotesque 
corruption and reliable, predictable, frequently 
comical Soviet incompetence. Members of my 
family lived in various refugee camps in Europe 
between 1944 and 1949, at which time they were 
sponsored by distant relatives to relocate to Cana-
da; some of their lasting and most intimate friend-
ships were made in the camps during those post-
war years. My parents had wed in Lübeck, Germa-
ny. 
It was their (and my) good fortune that our 
family ended up on the northwest shore of Lake 
Superior, in the small city of Port Arthur (now inte-
grated into a larger municipality, Thunder Bay), 
where I was born. If one envisions Lake Superior as 
having the shape of a wolf’s head, Thunder Bay is 
about where its eyes would be located. This beauti-
ful small city is situated on rolling hills overlooking 
the lake, and is home to one of the harshest (win-
ter) climates of any metropolitan area in Canada. It 
provided me with an outstanding primary and high 
school education at the hands of, and with the 
mentorship of, dedicated and devoted teachers 
who inspired a love of learning and a first-rate work 
Reflections 
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ethic, of which they themselves were emblematic. 
Very lucky break for me! Winters were long and 
brutal in Port Arthur. I well remember sitting in my 
high school classes, looking out onto the harbor – 
Port Arthur was a port city thanks to the St. Law-
rence Seaway (opened in the late 1950s, Queen 
Elizabeth II herself came to our fair city for the offi-
cial opening), which allowed ocean-going vessels to 
come into the Great Lakes. The harbor was still 
frozen in April and May, and I longed for warmer 
days – never dreaming then that I would spend 
most of my working career in a climate that can 
safely be described as endless summer. 
I was also fortunate to have support and en-
couragement from a wonderful father [Figure 1] 
who, as a single parent, raised me and my brother 
after our mother left in the early 1960s to begin a 
new life in the USA and my parents divorced. He 
died in 1980 but never a day goes by that I don’t 
think – with much love and gratitude – of him and 
his dedication to his sons and family, his generosity, 
support and kindness. Our loving and resourceful 
family included grandparents, aunts and uncles, 
eventually cousins, all trying to find their way in the 
brave new world into which they had been thrust 
by World War II and its aftermath and sequelae. As 
with many immigrant families trying to establish 
life in a foreign land, barely speaking English and 
with limited finances, extended family members 
(usually from three generations) occupied small 
apartments and houses, then eventually spread 
their wings and left to make lives of their own in 
their new homes, when they could finally afford 
them. My favorite home in those early days was a 
ramshackle house – little more than a cottage – just 
outside the Port Arthur city limits, with two tiny 
bedrooms and one miniscule bathroom (bath, no 
shower), situated on the banks of a small meander-
ing river and on a gorgeous piece of land. The 
property was also home to several massive pine 
trees and came to be known (by the Latvian expat-
riate community) as Eglaines (loosely translated, 
The Home of Tall Pine Trees). Seven of us called this 
home for many years. It had an old coal furnace in 
which fuel needed to be replenished during the icy 
winter nights, a task shared by my father and 
grandfather. My grandparents, who had been 
‘saimnieks and saimniece’ (the master and mistress 
of their household) and oversaw a large farm in 
Latvia, lovingly cultivated their gardens of flowers, 
berries and vegetables on the two acres that 
Eglaines occupied. I often wondered what it would 
be like to start one’s life over, at the age of 49 or 
50, in a foreign land and culture, as my resilient 
grandparents had; the task was easier – though no 
less challenging! – for my father and mother, who 
later became a medical technologist. My father and 
grandfather worked in the grain elevators that sur-
rounded the harbor (the grain coming from Cana-
da’s prairie provinces and destined to be loaded 
onto seaway-bound ships) until my dad became a 
real estate agent, then subsequently a real estate 
broker. My paternal grandmother worked as a do-
mestic. While I loved Port Arthur (that affection 
continues to this day) I yearned to pursue higher 
education in a larger center, and a variety of schol-
arships allowed me to do so at the University of 
Toronto (U of T), another lucky twist of fate. Being 
a Toronto resident introduced me to the joys (and 
challenges…) of big city metropolitan life, and I 
have enjoyed urban living ever since. I adore the 
buzz of large cities, almost without exception. Idyl-
lic country life, a dream for some, is not for me. 
 
 
Fig 1: My father Gunnar (Gunars) Vinters, 1925-1980 
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During the summer between my graduation 
from high school and the beginning of university 
(1968) I had the marvelous opportunity to work in 
the laboratory of a family friend (and my aunt’s 
godmother), Irene Grodums, who after immigrating 
to Canada had completed her Ph.D. and become a 
Virologist at the University of Saskatchewan in Sas-
katoon. Prof. Grodums instilled in me a respect for 
the importance of careful observation in tissue 
studies, whether done by light or electron micros-
copy (she worked on Coxsackie virus effects on the 
heart) and respect for experimental animals used in 
biological research. 
In the 1970s medical school was increasingly 
regarded as a place of graduate studies, following 
upon an undergraduate experience. My first degree 
was in Biology and most of my courses given in the 
Botany Department (these days, Plant Sciences). U 
of T undergraduate instruction was loosely based in 
one of the constituent colleges, and my academic 
(and residential) home was University College. I 
thrived on living on an historic campus situated in 
the middle of a world class city, one with a great 
sense of history. One of my first summer research 
jobs was in the Botany Department, studying the 
kinetics of water movement into and out of giant 
algae with Profs. Jack Dainty and Mel Tyree (both 
accomplished Biophysicists); this resulted in my 
first publication [1]. While in medical school at the 
University of Toronto (1972-76) I developed an 
abiding affection for the Neurosciences, though I 
realized I would never have the skill set, insights, 
patience or scientific acumen to be a solid basic 
neuroscientist. Our inspiring Professors included 
the legendary Neuropharmacologists Phil Seeman 
and Oleh Hornykiewicz; Dr. Seeman (probably one 
of the best lecturers I have ever encountered) had 
previously discovered how anesthetics and tran-
quilizers interact with cell membranes [2] and sub-
sequently contributed to the molecular under-
standing of complex genes that control dopamine 
receptor function, while Dr. Hornykiewicz was the 
discoverer of the dopamine deficiency [3] that 
leads to Parkinson disease. The other option was to 
choose a Clinical Neuroscience in which I would 
have both clinical responsibilities and an opportuni-
ty to do research and teaching. I decided to pursue 
postgraduate training in Neurology, having elimi-
nated Neurosurgery as a career path – I lacked the 
required stamina and manual dexterity, both (in 
addition to excellent clinical judgement) require-
ments of a first-rate Neurosurgeon. Fortunately, 
throughout my career I have had the opportunity 
to work with some of the very best in the latter 
field, in numerous productive collaborations and 
diagnostic challenges (see below). 
How Neuropathology chose me 
Neuropathology was a largely invisible special-
ty while I was in Medical School. Admittedly, in the 
early 1970s it was itself a fledgling discipline in the 
Clinical Neuroscience firmament, certainly in Cana-
da. We received wonderful lectures from Neuropa-
thologists – including Dr. Barry Rewcastle – but 
were never really apprised of how a Neuropa-
thologist spends her/his time and contributes to 
the diagnosis and understanding of neurologic dis-
ease. Indeed, we hardly knew that such individuals 
existed or how one went about becoming a Neuro-
pathologist, this despite several significant Neuro-
pathologic discoveries having been made at U of T’s 
Banting Institute on College Street, then home of 
the research components of the Pathology De-
partment. (Frederick Banting, the discoverer of 
insulin, was the first and is still one of the few Ca-
nadians to be awarded the Nobel Prize in Medicine 
or Physiology). The initial report of progressive 
supranuclear palsy [4] was co-authored by the 
great Jerzy Olszewski, though he had unfortunately 
passed on by the time I was in Medical School. I 
spent my internship year at the University of Alber-
ta Hospital in Edmonton, in retrospect a wise 
choice because it introduced me to the beauty of 
the rugged Canadian west (stunning prairie skies 
and amazing geography) and facilitated my meeting 
people who remain steadfast friends to this day. Of 
course that year also provided a terrific opportunity 
to learn important fundamentals of Medicine from 
energetic and knowledgeable instructors. The Uni-
versity of Alberta Hospital would, many years later, 
become a place where I would do an extended 
locum. 
I began training in Neurology in London, On-
tario in 1977 in the Department of Clinical Neuro-
logical Sciences (CNS) at the University of Western 
Ontario / UWO (subsequently renamed Western 
University). This Department represented a logical 
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fusion of talent from Neurosurgery, Neurology, 
Neuroradiology, and Neuropathology. Its leader-
ship included two legends of 20th century Neuro-
surgery (Charles G. Drake) and Neurology (Henry 
J.M. Barnett). London was also a major center for 
stroke research; the clinical specimens we were 
shown in surgical pathology and at autopsy confer-
ences inspired an appreciation and respect for the 
importance of cerebrovascular disease in Neurolo-
gy. The weekly 3-hour city-wide Clinical Neurosci-
ence rounds included presentations from all four of 
the sub-disciplines, including a clinicopathologic 
conference weekly or every two weeks. I was com-
ing to an important, somewhat uneasy career junc-
ture: Neurology felt like perhaps not quite the op-
timal choice of specialization for me. However… 
An inspirational figure during that first year of 
Neurology training came to be Dr. John C.E. Kauf-
mann, chief of Neuropathology at the (recently 
built) University Hospital on the main UWO campus 
in the north end of the city. Dr. Kaufmann (or JCEK, 
as his trainees knew him, Figure 2) had been re-
cruited from South Africa to be the first Neuropa-
thologist at UWO, and one of only a handful in 
Canada at the time. More than being a marvelous 
diagnostician, JCEK was the essence of a ‘gentle-
man and scholar’, someone who took responsibility 
for the wellbeing and mental and physical health of 
his trainees. I daresay most of us lucky to be in that 
multi-year cohort try to emulate JCEK in our own 
careers. He and his wife Suzanne Kaufmann loved 
art (they had an inspiring collection which included 
an Andy Warhol), entertaining on a grand scale, 
fine (exquisite) cuisine usually prepared in their 
own kitchen, good and witty conversation and 
travel. The presentations JCEK oversaw at the 
weekly Clinical Neuroscience rounds were marvels 
of clarity and insights into neurologic disease. 
Throughout that year of training in Neurology, I 
came to the conclusion that Neuropathology might 
be a more appropriate career path for me. Fortu-
nately, Dr. Barnett was very passionate about the 
vital importance of Neuropathology in neurodiag-
nostics. When I requested the possibility of doing a 
full year of Neuropathology training (then config-
ured as part of my Neurology residency) Dr. Barnett 
was favorable to the idea, as was JCEK. I embarked 
on the road to my career as a Neuropathologist 
with some trepidation, but a passion for the study 
of the anatomic basis of neurologic diseases using a 
multitude of special stains, which in those days 
(late 1970s) were, together with electron micros-
copy, the ‘gold standard’ for neuropathologic inves-
tigations. Oh yes, things have changed! 
 
 
Fig 2: Dr. John C.E. Kaufmann, Chief of Neuropathology, Uni-
versity Hospital, London, Ontario, Canada 
 
My other mentors in London were Dr. Melvyn 
J. Ball, who was already a prominent Alzheimer 
researcher, and Dr. Joseph Gilbert [Figure 3], who 
had trained in Neurology and Neuropathology in 
Cleveland, though practiced the latter. Neuropa-
thology in Canada is configured as a specialty ra-
ther than a ‘subspecialty’ requiring Fellowship 
training. JCEK and Joe Gilbert were in charge of NP 
training at the two major UWO teaching hospitals, 
University and Victoria, and possessed complemen-
tary, mutually reinforcing didactic skills. JCEK was 
an experienced, meticulous and insightful neuro-
histologist. Joe Gilbert was a master of providing 
clinicopathologic insights based upon careful corre-
lation of neuropathologic findings with clinical signs 
and symptoms (structural brain imaging in the late 
1970s was still in its infancy). The experience of 
working with them both and learning from them 
was exhilarating, humbling and yes – a little daunt-
ing. 
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Fig 3: Dr. Joseph J. Gilbert, Neuropathology mentor, London, 
Ontario 
 
Joe Gilbert also suggested to me a translation-
al research project that would determine and de-
fine my research interest for the coming decades: 
diseases of the cerebral microvasculature. As a 
stroke referral center, UWO was encountering 
many patients with lobar intracerebral hemorrhag-
es caused by, or at least associated with, cerebral 
amyloid angiopathy (CAA). Joe suggested that we 
collect our cases of (putative) CAA-related brain 
hemorrhage and write a descriptive paper on this 
association; a companion study would assess the 
topography and severity of CAA in relation to brain 
aging. In the late 1970s and early 1980s (well be-
fore the discovery of beta-amyloid protein in 1984, 
see below) CAA was evaluated by the use of Congo 
red staining and polarization microscopy (alterna-
tively using thioflavin stains and fluorescence mi-
croscopy). The ‘topography/severity of CAA with 
age’ study was performed simply by staining a large 
number of brain sections, from uniformly sampled 
autopsy brains, with Congo red and evaluating CAA 
in these. The two resultant manuscripts went 
through several drafts, were eventually submitted 
to the journal Stroke as ‘back-to-back papers’, and 
published in 1983 [5,6]. It is gratifying that the find-
ings we described using fairly primitive (by today’s 
standards) technology have been replicated using 
beta-amyloid immunohistochemistry in later stud-
ies; it is perhaps especially satisfying that the pa-
pers are still being cited 37 years after their publi-
cation (combined total citations of 500+ per the 
Web of Science). Examining the pathogenesis and 
consequences of CAA and other microangiopathies 
in the brain would constitute a major theme of my 
subsequent research endeavours.  
My NP residency was spent feasting on the in-
struction and support of my mentors and the re-
markable and stimulating milieu created by the 
clinical Neurologists, Neuroradiologists and Neuro-
surgeons at UWO. This showed and highlighted the 
importance of collaborative activities in under-
standing complex neurologic diseases. Luminaries 
in Neurology and Neurosurgery (Fred Plum, Ray-
mond Adams among them) were frequent visitors 
to this small but ‘neurologically important’ city half 
way between Toronto and Detroit. One of my in-
terests was in the effects on cerebral arteriovenous 
malformations (AVMs) of agents used in novel em-
bolization therapies that were just being devel-
oped, many of them at UWO. Two skilled endovas-
cular specialists (Drs. Fernando Vinuela and Allen 
Fox) were pioneering new agents and approaches 
to non-surgical therapies for vascular brain lesions, 
and continued to do so throughout their careers. 
When these lesions (usually AVMs) were subse-
quently resected, they showed unique and some-
times dramatic reactive changes caused by the 
embolotherapy agents (about which more later…). 
Many of my research interests have been driven by 
clinical or clinicopathologic questions. Here were 
two large and important ones: Why (and how) do 
embolotherapy agents work through their interac-
tions with vessel walls in vascular malformations? 
What might be some neuropathologic clues to why 
they sometimes fail? They were also questions that 
could be effectively addressed by simple observa-
tion (using routine stains) of previously embolized 
lesions when they made their way to the Surgical 
Neuropathology laboratory.  
There was discussion of my returning on facul-
ty to UWO, but only after I had spent some time 
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developing basic research skills pertinent to the 
study of cerebrovascular disease. The University 
would provide or facilitate funding for my research 
endeavours, but I had the freedom to choose a 
laboratory in which I might develop appropriate 
experimental techniques and skills that I could re-
patriate to UWO. At that time, some of the most 
exciting work on cerebral microvascular biology 
(especially the blood-brain barrier/ BBB) was being 
done using cell biologic techniques in the laborato-
ries of Drs. Pasquale (Pat) Cancilla [Figure 4] and 
Michael N. Hart [Figure 5] at the University of Iowa 
(U of I) [7,8]. It was arranged that I would spend 
two years working with them, after a 6-month pe-
riod refining my diagnostic skills in Pediatric Neuro-
pathology with Dr. Margaret Norman in Vancouver; 
Marg became and remained a good friend for the 
rest of her life. 
 
 
Fig 4: Dr. Pasquale (Pat) and Enid Cancilla, undated photograph 
 
Trying my hand at (basic) research 
I arrived in Iowa City (in which the University 
of Iowa is located) in January 1982, in the midst of 
a nasty midwestern blizzard. During a lonely week-
end in a slightly seedy motel in Coralville (a suburb 
of Iowa City) I frequently thought: ‘What on earth 
have I done?’ During my first day in the new labora-
tory environment at the U of I, Pat Cancilla asked if 
I could go with him for a cup of coffee. Then 
 
 
Fig 5: Dr. Michael Noel Hart 
 
came the bombshell: he had just accepted the 
Chair of Pathology position at University of Califor-
nia Los Angeles (UCLA). He suggested that, since I 
had independent funding that was not tied to a 
specific institution, I might either stay at the U of I 
and work with Michael Hart, or move with him to 
UCLA. As I looked outside at the heavy snowfall and 
felt the subzero temperature en route back to the 
lab, I had essentially made my decision, and moved 
with Dr. Cancilla to UCLA that summer. During the 
six months I resided and worked there, however, I 
developed an affection for Iowa City, sometimes 
described as the ‘Athens of the Midwest’—famous 
for its world class medical center (including brilliant 
translational neuroscience and behavioral neurolo-
gy) and the Iowa Writers Workshop. My colleagues 
there included Drs. Jonathan Fratkin and David 
Beck, the latter an outstanding Neurosurgeon (then 
still a resident) bursting with excellent research 
ideas that might optimize the use of cultured cells 
in understanding BBB physiology and abnormalities 
[9]. 
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UCLA, destined to become my academic home 
for most of the remainder of my career (though 
that decision was still in the future), was research 
heaven for a young scientist. It was fun helping to 
set up Pat Cancilla’s laboratory (our senior techni-
cian at the time was Jim Bready) with top-of-the-
line equipment and facilities that were the perks of 
being a newly recruited Chair and entering the aca-
demic milieu of a major research university. Our 
‘lab warming’ party was a smash hit throughout the 
medical center. Pioneering studies of cerebral mi-
crovessels (especially the BBB) were ongoing in the 
laboratories of two ‘Bills’ – William Pardridge and 
William Oldendorf. Dr. Oldendorf had previously 
(1975) won the Lasker Award, and probably de-
served the Nobel, for suggesting the principles that 
led to computerized tomographic (CT) scanning, 
but was also an innovative and creative investigator 
looking at the physiology of the BBB, especially 
using isotope tracer techniques. He was also Bill 
Pardridge’s mentor. Pat Cancilla’s lab became part 
of an informal consortium of investigators (also 
including Drs. Judith A. Berliner, an experienced cell 
biologist, and Eain Cornford at the West LA VA 
Medical Center) interested in cerebral microvascu-
lature (especially its endothelium) and optimal 
ways to study it. Our laboratory was mainly in-
trigued by the potential use of tissue culture ap-
proaches and had been able to isolate and culture 
endothelial and smooth muscle cells from brain 
microvessels, initially from mouse brains but even-
tually (some years later) even those derived from 
human corticectomies for intractable epilepsy. 
I was also smitten by the city of Angels, Los 
Angeles. It represented a far different world from 
the one in which I grew up. L.A. was (and is…) a city 
with a near perfect climate (summer and winter), 
far cleaner air than is widely believed, stunning 
geography with canyons, hills and flatlands, a bril-
liant seaside location on Santa Monica Bay, and 
remarkable ethnic and cultural diversity. It reminds 
itself almost daily that it is the ‘world capital of the 
entertainment industry’, which is probably true, 
and ‘the creative center of the planet’ – the latter a 
claim that London (England), Amsterdam, Tokyo, 
Paris and a few other cities might dispute. I re-
member reading that the German novelist Gunther 
Grass had once described Berlin as representing a 
city that ‘faced the realities of the 20th century’ 
(this may be an erroneous recollection…), and 
thinking that would probably apply quite accurately 
to L.A. in the late 20th and early 21st centuries. 
Though I at first lived near the UCLA campus, I 
found myself spending many weekends at Venice 
Beach, where I have now had a home for the past 
30+ years. (Rationale: If you live near the Pacific 
Ocean, why not at one of the most famous beaches 
in the world?) As I was nearing the end of my post-
doctoral fellowship, I was working in the lab on a 
Saturday morning. Pat Cancilla called me into his 
office (immediately adjacent to the laboratory) and 
rather directly asked if I might be interested in a 
UCLA faculty position – one had just come open in 
Neuropathology because of the retirement of Dr. 
Jann Brown. We discussed the possibility briefly. 
This was the second time in my career that a casual 
chat with Pat Cancilla would alter the course of my 
career. 
Return to London, Ontario and UWO 
(briefly) 
Because of visa issues and funding, I was 
committed to return to London, Ontario, but my 
faculty job there was a ‘soft money’ position, unlike 
the tenure track post for which I was being consid-
ered at UCLA. I had formally applied for the UCLA 
faculty position while still a postdoc there, inter-
viewed for it, and eventually (a few weeks after 
returning to London, Ontario) was offered and de-
cided to accept the job. It was a decision made over 
an agonizing weekend during which I weighed the 
many pros and cons – the University of Western 
Ontario would have made a wonderful academic 
home for me, and London a welcoming and very 
livable city (I had already bought a home there). 
John Kaufmann and Joe Gilbert were amazing men-
tors and colleagues. Yet I had enjoyed my postdoc 
at UCLA so much… that I felt I had to ‘give it [the 
faculty position] a try’. Having heard that American 
academic medicine could be rather brutal and 
fiercely competitive (though I had seen little evi-
dence of this during my postdoc), I began to won-
der whether I had the stomach for this. I rational-
ized the decision by thinking I would remain at 
UCLA for 2-3 years, then return to London, Ontario 
(assuming a position was still open there…). At the 
appointed time, I considered this move back, and 
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decided to remain at UCLA, where I am (part time, 
semi-retired) today. 
My 18 months in London (pending receipt of 
the green card / permanent resident status that 
would allow me to take up life in the USA) were 
delightful and rewarding both professionally and 
personally – so much so that I began having some 
doubts as to whether I had made the correct deci-
sion in accepting the UCLA job. (Timing is every-
thing. Were I making this same career-changing 
deliberation in the current unwelcoming USA im-
migration climate, I would almost certainly have 
stayed in London!) I managed to set up a small 
tissue culture laboratory at University Hospital – 
thanks to the fact that a fully equipped laboratory 
with appropriate equipment had just been made 
available by a departing or retiring faculty member. 
We were able to successfully culture endothelial 
and smooth muscle cells from human cerebral mi-
crovessels [10]. I continued to have an interest in 
‘embolized AVMs’. As a result of the neurosurgical 
skills and expertise of Drs. Charles Drake and Sid-
ney (‘Skip’) Peerless, brilliant endovascular therapy 
experts Vinuela and Fox (see above) and their re-
spective teams, London and UWO attracted com-
plex AVM cases from around the world that might 
be candidates for this unique therapy. If one is go-
ing to do translational research, it helps to have a 
unique collection of abundant clinical and patho-
logic specimens to study – and our Neuropathology 
laboratory had just such an array of treated AVMs, 
an amazing experiment of nature, though one ad-
mittedly manipulated by physicians. With the help 
of JCEK and a very industrious undergraduate stu-
dent (Mark Lundie) I set about a careful examina-
tion of AVMs that had been treated by emboliza-
tion with isobutyl cyanoacrylate, one of the widely 
used embolotherapy agents at that time. (It is an 
agent that is injected through a catheter in liquid 
form, but polymerizes at various rates depending 
upon how much contrast medium is in the mixture. 
With this agent, timing of the polymerization pro-
cess was of paramount importance – if it polymer-
ized too quickly, the catheter could become stuck 
to the intima of the AVM ‘feeding’ vessel; if too 
slowly, it would end up passing through the AVM 
and into a treated patient’s lungs.) We had vascular 
malformations with a wide range of post-
embolization intervals that allowed for inferences 
about how this polymer was interacting with ab-
normal vessel walls in AVMs. We put together a 
significant (and rather unique) data set, which I 
brought with me to UCLA when I returned there in 
July, 1985, hoping I would have the time to analyze 
it in detail and prepare a manuscript. 
 
 
Fig 6: Dr. Michael A. Farrell, friend, colleague and ‘partner in 
crime’ 
 
I also had the good fortune to meet, during 
that 1 ½ years back at UWO, Dr. Michael Farrell 
[Figure 6], a newly arrived Neuropathology trainee 
from Dublin, Ireland. Michael became a great 
friend and colleague during that time and after he 
returned to a consultant post in Dublin. Over the 
years, we have written many papers (see below) 
and co-authored a textbook, he has often visited 
L.A. (even doing a mini-sabbatical in my laboratory 
during the early 1990s), and I have gone to Dublin 
dozens of times; it is on my list of favorite cities 
around the globe. Great and generous friend. 
Through Michael I eventually came to know the 
small but vibrant Irish Neuropathology community, 
including Drs. Katie Keohane and Francesca Brett. 
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On faculty at UCLA 
How does one summarize 35 years of academ-
ic and diagnostic work at one institution? There are 
many things I love about UCLA: the physical beauty 
and location of the campus in Westwood (the UCLA 
Medical Center, now Ronald Reagan UCLA Medical 
Center, is at the southern edge of the main cam-
pus), the collegial and collaborative nature of the 
faculty, the wealth of expertise in all aspects of 
basic and clinical science, especially neuroscience, 
talented and intelligent students and trainees, and 
the cultural and ethnic diversity of both students 
and faculty who are committed to scholarly work. 
Yes, there are things not to like (but one endures 
them…): the numbing, frequently obstructive bu-
reaucracy, the ‘bend over backwards’ approach to 
being politically correct are among them. 
I returned to L.A. and the UCLA family the first 
week of July, 1985. I used the ‘down time’ in setting 
up a small research laboratory, to finesse two pro-
jects. One was collating the embolized AVM data 
into a coherent story. As I wrote the manuscript 
and put the results into perspective, I thought the 
material was sufficiently novel that it might be wor-
thy of submission to the prestigious New England 
Journal of Medicine, with the thought that ‘nothing 
ventured, nothing gained’. As I put the manuscript 
in the mail (YES, what we now call snail mail...) I 
was already reformatting the paper for a lower 
level, less prestigious journal because of the cer-
tainty of rejection. Then a few days later I received 
a surprising phone call from the NEJM telling me 
the manuscript had been accepted, with minimal 
revisions; they were calling me to verify that there 
was no overlap with a review article on cyanoacry-
lates we had recently written – I assured them 
there was none [11]. The NEJM paper was pub-
lished in 1986 [12] and represents one of my two 
appearances as an author of a paper in this high-
profile venue, the second coming almost exactly 20 
years later as a co-authored contribution on a total-
ly different topic [13]. My other project was to 
write a review article on (what else?) CAA – I sug-
gested this to Henry Barnett, then executive editor 
of Stroke, and he liked the idea. That paper eventu-
ally appeared (after a few revisions) in 1987 [14] 
and is still frequently quoted today. 
In the meantime, I resumed my tissue culture 
studies but decided to embark on other scientific 
adventures. While I was impressed by the simple 
questions that could be addressed (and answered) 
using in vitro methods, I was (like many investiga-
tors) concerned about how these phenomena 
could be understood in the context of complex 
multi-cellular tissues and organs, especially in the 
brain. Being a junior faculty member at UCLA was 
the academic equivalent of being a child at a candy 
store. Colleagues were always approaching one 
about working on any variety of projects, some 
utilizing human CNS specimens, others exploiting 
interesting animal models, transgenic and knockout 
mice, etc. Neuropathologists were and are in the 
unique position of understanding the structure of 
the nervous system (normal and abnormal), and 
how best to study it. I re-established a close collab-
oration with William Pardridge (see above), an En-
docrinologist in the Dept. of Medicine who was 
interested in the biochemistry (and eventually mo-
lecular biology) of transport mechanisms through 
the BBB, but was now also looking for a way to 
study abnormalities (diseases?) of small blood ves-
sels. We had many discussions about cerebral amy-
loid angiopathy (CAA), which of course affects arte-
rioles and capillaries and, together with arteriolo-
sclerosis, is one of the two most common micro-
vasculopathies found in the brain. In 1984, Glenner 
and Wong [15] had isolated the ‘A4’ protein from 
amyloid-laden meningeal vessels of an Alzheimer 
patient. Bill Pardridge was amazingly skilled at mak-
ing antibodies and proceeded to make a polyclonal 
antibody to ‘A4’, using the partial sequence of the 
peptide provided by Glenner and Wong in their 
paper. It worked magnificently in immunohisto-
chemical protocols to demonstrate both senile 
plaques and CAA, resulting in several publications 
[16,17]. Bill Pardridge was also the best person in 
the School of Medicine to review the draft of a 
grant proposal; I am eternally grateful for his merci-
less critique of one of my first independent Nation-
al Institutes of Health (NIH) proposals, which 
through his intervention helped me transform an 
unfocused and improbable set of studies into a 
fundable application.  
My Chief of Neuropathology was M. Anthony 
Verity, and we divided the service and diagnostic 
commitments equally – each of us covered 6 
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months of the year. My interests were obviously in 
cerebrovascular disease and dementia, Tony’s in 
neurotoxicology and neuromuscular diseases. 
When one of our outstanding Neurologists, Dr. 
Jeffrey Cummings, decided to submit an NIH (Na-
tional Institute on Aging) grant that, if successful, 
would fund an Alzheimer Disease Center (ADC) at 
UCLA in the late 1980s/early 1990s, I seemed the 
logical choice to head the Neuropathology Core 
and Brain Bank. We were funded on the first sub-
mission and I was thrilled to formally become part 
of the Alzheimer research enterprise at UCLA, even 
though my main academic focus (CAA and related 
microvascular diseases) was at the periphery of 
most debates on AD pathogenesis. This situation 
has changed drastically in recent years. It is also 
worth noting that Glenner and Wong had isolated 
A4 from amyloid-laden meningeal microvessels (‘a 
novel cerebrovascular amyloid protein’) rather than 
senile plaques (SPs); as is now well known, the anti-
A4 antibody indeed labels SPs as well as CAA, but 
not neurofibrillary tangles, despite initial claims 
that it might. 
Over the years until his departure from UCLA, 
Jeff Cummings was an amazing leader: a superb 
diagnostician and organizer who supported basic 
research efforts and consistently brought out the 
strengths in investigators and his staff. And oh yes, 
he was a masterful fund raiser, successful in obtain-
ing private donations that were crucial to support-
ing the ADC when NIH funding lapsed or became 
thin. He eventually secured an endowment that led 
to re-naming of the ADC as the Mary Easton Alz-
heimer Center. I had obtained NIH and other fund-
ing for my own projects within 3-4 years of arriving 
at UCLA, but have always felt most at home scien-
tifically in the environment of a collaborative Cen-
ter or Program Project Grant; pieces of these have 
constituted most of my research efforts and fund-
ing support while on faculty at UCLA.  
Of course, in the early to mid-1980s other 
events were taking center stage in the world of 
medicine: the disease that was eventually named 
acquired immune deficiency syndrome (AIDS) pre-
sented in a handful of gay men, initially studied in 
New York City and L.A. (Please also see Herbert 
Budka’s thorough and excellent description of the 
beginnings of this epidemic in his Reflections piece 
published earlier this year.) As Pathologists, we 
were witnessing the evolution of a feared illness 
that, at the time and for many years to come, had 
no effective treatment and was almost uniformly 
fatal. By the mid-1980s it was known to be caused 
by the retrovirus HIV-1 (initially named HTLV-III). In 
that same time frame, thanks to the work of many 
investigators including George Shaw, Beatrice 
Hahn, Clayton Wiley, Leroy Sharer and others, it 
became appreciated that HIV frequently infected 
the brain in both children and adults, causing a 
syndrome initially described as AIDS dementia 
complex (in adults) though later re-named several 
times. But I’m getting ahead of myself… 
Pathologists have now (and always have had) 
a key role in providing morphologic evidence for 
unique disease mechanisms – some of them based 
simply upon careful observation of novel but con-
vincing histopathologic changes within tissues. 
Consider, as one example outside the nervous sys-
tem, the astute observation by Robin Warren 
(pathologist) and Barry Marshall (gastroenterolo-
gist) of ‘unidentified curved bacilli in the stomach of 
patients with gastritis and peptic ulceration’. This 
description of Helicobacter pylori, initially published 
in Lancet (in 1984) eventually led to their being 
awarded the Nobel Prize in 2005 because the ob-
servation led to a complete re-examination of the 
rationale for ways to treat peptic ulcer disease, a 
major paradigm shift. Moving back into the CNS, 
Neuropathologists have made countless key obser-
vations (often in human biopsy or autopsy speci-
mens) pertinent to the pathogenesis of neuro-
degenerative disease, intractable epilepsy, stroke, 
developmental disorders, tumors, and the list goes 
on. With the beginning of the AIDS epidemic, here 
was another opportunity to see a new infectious 
disease evolving before our eyes. This might be 
(often is…) called ‘opportunistic research’, with the 
slight implication that it is not as challenging or 
important as ‘basic research’. However, when 
unique opportunities to carefully study a human 
disease present themselves, one would be foolish 
not to take advantage. At UCLA Center for the 
Health Sciences (CHS), one of the bright young res-
idents from Canada, Karl Anders [Figure 7], sug-
gested we review the neuropathologic features of 
our large and growing autopsy collection of brains 
from AIDS patients. Karl and I, both recent arrivals 
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from Canada, bonded as soon as I arrived at UCLA. 
We had both grown up in two cities located about 
400 miles apart (Karl in Winnipeg), were raised in 
the households of immigrant families, and we both 
liked looking at slides – a lot of slides. 
 
 
Fig 7: Dr. Karl H. Anders, Pathologist and frequent collaborator 
on projects, currently in Calgary, Alberta, Canada 
 
We also engaged in this neuropathologic en-
terprise the collaboration of Dr. Uwamie Tomiyasu 
[Figure 8], an amazingly insightful, organized, help-
ful and collegial Neuropathologist at the West L.A. 
VA Medical Center (who over the years became a 
close friend), and involved a promising young UCLA 
medical student Wayne Guerra in the project. Karl 
Anders had been the first author on the report of 
our initial series of AIDS autopsy cases (less than 
30) written while I was still a research fellow at 
UCLA. We had submitted this detailed report to 
Clinical Neuropathology. The manuscript had been 
almost immediately accepted for publication in late 
1983 or early 1984. Then, to our amazement and 
shock, Clinical Neuropathology ‘sat on’ this very 
topical manuscript for over 2 years before publish-
ing it – in the meantime printing (arguably) less 
impactful and timely studies that had clearly been 
accepted after our paper [18]. By 1986 we had 
compiled data on almost 90 AIDS autopsy cases, 
and submitted this updated report to the American 
Journal of Pathology, where it was accepted with 
minimal revisions, and published a few short 
months after the much delayed Clinical Neuropa-
thology paper [19]. Karl and I wondered whether 
someone reading both papers (published in 1986) 
would question how we accumulated 60 new AIDS 
cases in a few short months, which of course we 
had not. 
The neuro-AIDS work took some interesting 
twists and turns, largely as the result of collabora-
tions with some of my formidably talented col-
leagues in Virology and Neurology interested in 
viral neuropathogenesis. I co-authored two papers 
together with David Ho and his research group 
while he was briefly on staff at Cedars Sinai Medical 
Center in Los Angeles [20,21]; these are the only 
two publications I have written with a physician-
scientist who would eventually become Time mag-
azine’s Man/Person of the Year in 1996. (I very 
much enjoyed basking in the reflected glow of Da-
vid’s richly deserved fame.) I was also approached 
by a brilliant and productive retrovirologist, Dr. 
Irvin S.Y. Chen, who had trained with one of the 
discoverers of reverse transcriptase (Howard Temin 
at the University of Wisconsin) before becoming a 
faculty member at UCLA at about the same time as 
me. Irvin was (and remains) keenly interested in 
the molecular pathogenesis of interactions be-
tween HIV and the brain. His laboratory used au-
topsy brain and CSF specimens from neuro-AIDS 
subjects to characterize a neurotropic strain of HIV, 
and exploited PCR to quantify HIV viral load in the 
CNS of affected patients [22,23]. It seemed an ideal 
collaboration between a talented basic virologist 
and someone (HVV) interested in morphologic 
brain changes induced by HIV. At the same time, 
my laboratory remained fascinated by the interest-
ing opportunistic infections (OIs) – especially other 
viral agents, that can cause puzzling varieties of 
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devastating neurologic diseases in immunosup-
pressed AIDS patients. Cytomegalovirus was one of 
the viral OIs capable of producing variable CNS 
disease in AIDS, including (at its worst extreme) 
severe encephalitis, ventriculitis and myeloradiculi-
tis, yet minimal abnormalities in others. Contribu-
tors to these studies included Karl Anders, a post-
doctoral fellow from Germany, Dr. Regina von Ein-
siedel and Marcia Cornford, who was one of our 
first trainees in Neuropathology and is still a faculty 
member at Harbor-UCLA Medical Center in Tor-
rance, California [24,25]. I became the Pathologist 
of record for the UCLA site of the Multi-Center AIDS 
Cohort Study (MACS, PI Dr. Roger Detels), one of 
the longest funded NIH projects in history. Karl 
Anders and I co-authored a monograph on the neu-
ropathologic features of AIDS [26].  
 
 
Fig 8: Dr. Uwamie Tomiyasu, (deceased 2004), former Neuro-
pathologist, West L.A. VA Medical Center and UCLA faculty 
member, friend 
 
By the mid- to late 1980s and into the 1990s 
there were other interesting developments in 
UCLA’s active epilepsy surgery programs. It already 
had a longstanding research effort on temporal 
lobectomy for intractable temporal lobe seizures, 
under the capable and inspiring direction of Jerome 
(‘Pete’) Engel (Neurologist) and Paul Crandall (Neu-
rosurgeon). Pete was, and continues to be, one of 
the great advocates for bringing the possibility of 
curative temporal lobe surgery or ‘neocorticecto-
my’ to epilepsy patients throughout the world. Paul 
was a meticulous Neurosurgeon who provided us 
with anatomically intact (including the hippocam-
pus) temporal lobes. The arrival at UCLA of pediat-
ric Neurosurgeon Dr. Warwick Peacock from South 
Africa in the mid-1980s ushered in a new era of 
pediatric epilepsy surgery. Using high resolution 
neuroimaging (including structural and metabol-
ic/positron emission tomographic imaging) modali-
ties linked with electrocorticography, Warwick and 
the Pediatric Epilepsy group (under the visionary 
leadership of Drs. Donald Shields and Raman 
Sankar) developed the concept that generalized 
epilepsies in infants and children (e.g. leading to 
infantile spasms) might have a focal origin – a ‘zone 
of cortical abnormality (ZCA)’ within the cerebral 
cortex – and that removing such a focus might ef-
fectively treat the seizures. At the time, this was 
considered a radical, almost heretical – possibly 
even dangerous! – approach, but our clinicians 
were certain they had convincing evidence for the 
ZCA and proceeded with corticectomies for intrac-
table infantile and pediatric epilepsy, sometimes 
removing a significant portion of one cerebral hem-
isphere in an infant. The challenge for Neuropa-
thologists was to identify what the underlying 
structural abnormality (abnormalities) causing the 
seizures might be. Again, we were handed the op-
portunity to study unique specimens that might 
explain important clinical signs and symptoms. 
By the late 1980s and early 1990s we had ac-
cumulated a significant experience with these spec-
imens. Fortuitously, my friend and colleague Dr. 
Michael Farrell came over from Dublin in 1991 to 
do a mini-sabbatical at UCLA, and set about collat-
ing the data on our collection of pediatric epilepsy 
surgery cases. The most common neuropathologic 
change (especially among the youngest sympto-
matic patients) was a malformation of cortical de-
velopment that had first been described by David 
Taylor and colleagues in the 1970s. It had a striking 
resemblance to the tubers found within the brains 
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of patients with tuberous sclerosis complex (TSC) 
even though affected individuals showed none of 
the visceral or cutaneous stigmata of this neurocu-
taneous disorder [27]. Ironically, ‘tuberectomy’ has 
now become an accepted treatment for some TSC 
patients with intractable seizures. A much less 
common finding among corticectomies was an 
inflammatory disorder first described in 1958, 
Rasmussen encephalitis (RE). Dr. Farrell was first 
author on our initial ‘pediatric corticectomy’ paper 
[28] and we continued to collaborate on other pro-
jects, including one aimed at elucidating the de-
tailed neuropathologic changes of RE [29]. Paul 
Mischel, then a Neuropathology Fellow and now a 
leading neuro-oncology researcher at UC San Die-
go, was a lead author on a paper in which we pro-
posed a ‘grading’ scheme for the (as yet poorly 
understood) condition of cortical dysplasia (CD) 
[30] – a scheme that served its purpose in the mid-
1990s and has been superseded by others, as it 
should be.  
The team of clinicians and basic researchers 
who collaborated in the Pediatric Epilepsy Surgery 
program was a pleasure to work with. This was 
team science at its finest – everyone in the group 
respected (and utilized) the unique skills of all oth-
er basic and clinical neuroscientists, and the result-
ing multi-disciplinary studies benefited from this 
synergy. Experts in Linguistics, Neuropsychology, 
Neuroradiology, Neurophysiology and Psychiatry 
interacted productively with a simple Neuropa-
thologist. Our goal was not only to understand 
what structural changes in the brain may have con-
tributed to the catastrophic seizure disorder, but 
how corticectomy might impact a child’s behavior 
and language development. Dr. Gary Mathern, a 
UCLA-trained Neurosurgeon and protégé of Paul 
Crandall and Warwick Peacock, eventually became 
the surgeon-of-record for most of the pediatric 
epilepsy cases. Dr. Mathern also has the ‘soul of an 
investigator’, is possessed of enviable organization-
al skills and leadership qualities, and fostered new 
and exciting directions in which the UCLA Pediatric 
Epilepsy Surgery Program might move, places 
where it might thrive. Dr. Carlos Cepeda, Michael 
Levine, (the late) Robin Fisher, Veronique Andre 
and others became integral to the study of electro-
physiological and morphological properties of the 
epileptogenic tissue originating from infants and 
children with intractable seizures [31-33]. Dr. Nori-
ko Salamon in Neuroradiology contributed her 
powerful diagnostic insights and observations 
[34,35]. In 2006, and based upon our morpho-
anatomical and electrophysiologic studies, we pro-
posed the ‘Dysmature cerebral developmental hy-
pothesis’ as a possible etiology for CD [32]. At the 
same time, we continued to explore the possible 
relationship of sporadic CD to TSC tubers. 
The genes that are mutated to cause TSC (first 
TSC2, then TSC1) had been discovered in the 1990s; 
we made probes to the relevant gene transcripts 
and eventually antibodies to the gene products 
(tuberin and hamartin), using these to study gene 
expression in normal brain, tubers of TSC and spo-
radic cortical dysplasia [36-39]. This led to a valua-
ble collaboration with leading TSC researcher Dr. 
David Kwiatkowski and his associates in Boston – 
which included sophisticated molecular genetic 
analysis of many of our corticectomies and even 
allowed us to examine a novel animal model of 
TSC, one of the first to be developed by his group 
[40,41]. 
I became UCLA’s Chief of Neuropathology in 
1993, when Tony Verity decided to take advantage 
of the University’s ‘voluntary early retirement in-
centive plan, VERIP’, though thankfully he re-
mained active as an Emeritus faculty for many 
years, sharing his expertise in neuromuscular diag-
nosis (Dr. Negar Khanlou became his protégé and 
successor) and his passion for cricket. Tony was 
also an excellent artist and I am proud to have one 
of his paintings on the wall of my living room in 
Venice. I served in the Chief of Neuropathology 
post until I myself took ‘semi-retirement’ in 2016, 
and had the pleasure to mentor junior colleagues 
who went on to highly successful careers: Cynthia 
Welsh, Dennis Chute, Jeff Twiss, Paul Mischel 
among them. Dr. William Yong, my current Chief, 
was a medical student who I tutored in the 1980s, 
later a Neuropathology Fellow in our program, and 
has been a marvelous colleague – alas, recently 
departed for a position at University of California 
Irvine Medical Center. For several years, I was hon-
ored to hold the Sarkaria Chair in Diagnostic Medi-
cine.  
In the mid-1990s I was asked by University of 
Southern California (USC) Neurologist Dr. Helena 
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Chui to become part of a California-wide study she 
was planning, examining the clinical, neuroimaging 
and neuropathologic substrates of individuals with 
documented (or at risk for) cerebrovascular dis-
ease. The overarching (and perhaps overly ambi-
tious) theme and goal of the program project grant 
was to highlight the neurobehavioral, imaging and 
neuropathologic features of ischemic vascular de-
mentia (IVD), on the assumption that such an entity 
exists. Helena was an inspiring and superbly orga-
nized leader, and an insightful judge of character, 
the consummate solver of problems. NIH Program 
project grants (PPGs), including the one that fund-
ed this study, involve the interactions of widely 
differing personalities and the principal investigator 
of such an endeavor (i.e. Helena Chui) needs to 
manage those people and their disagreements as 
well as their productive interactions. Our group 
involved Neuropsychologists, Epidemiologists, Neu-
rologists, and experts in neuroimaging: Bruce Reed, 
Dan Mungas, Mike Weiner, Bill Jagust, Ling Zheng, 
Wendy Mack and many others. My fellow investi-
gators in the Neuropathology Core included Wil-
liam Ellis (UC Davis), Ewa Borys (now in Chicago) 
and Chris Zarow (then a talented neuroanatomist 
at USC). Our studies, over the long duration of the 
IVD-PPG, showed that ‘pure’ IVD was a compara-
tively rare phenomenon, but that risk factors for 
cerebrovascular disease probably contribute to 
accelerated brain aging, and even some compo-
nents of Alzheimer disease (AD), a view that is gain-
ing traction in the neuroscientific community and a 
subject that has generated much research interest 
[42-44]. Two papers from the IVD group focused on 
the ‘neuropathologic substrates’ of cognitive im-
pairment resulting from ischemic brain lesions 
[45,46], though crucial neuropathologic data were 
integrated into many other publications. For sever-
al years, I have had an enjoyable collaboration with 
Dr. Wolff Kirsch, a Neurosurgeon at Loma Linda 
University Medical Center (approximately 100 miles 
east of L.A.) who, rather than quietly retire after a 
stellar career in Neurosurgery, decided to become 
a researcher with an interest in, among other 
things, brain aging and cerebral amyloid angiopathy 
(see Table 1). Dr. Kirsch is devoted to the idea of 
eventually preventing or treating this microangiop-
athy and has enlisted materials from the Easton 
Center Brain Bank in studies with that goal. Very 
entrepreneurial and creative Neuroscientist and 
much fun to work with in joint projects.  
As the above summary indicates, much of my 
research has been collaborative and translational. 
Grant reviewing agencies have, I am quite certain, 
considered it ‘scattershot’ and unfocused. ‘Can 
Vinters not focus on a single topic?’ – the answer is 
clearly ‘no’. I’ve enjoyed all of the disparate re-
search endeavours in which I have been involved. 
They have included interactions with investigators 
possessed of unique talents and abilities, providing 
the possibility of forming irresistible, tantalizing 
scientific alliances. Table 1 summarizes the key 
individuals with whom I have worked and pub-
lished most intensely over the years; it is by no 
means a complete list. My advice to people enter-
ing Neuropathology would be to choose your col-
laborators carefully, wisely. Consider individuals 
who can bring projects to completion in a timely 
fashion and make effective use of a Neuropa-
thologist’s unique skill set. Have I myself been suc-
cessful in following that mandate for timely com-
pletion of projects? Well… not always… but often 
enough. Work with people who will criticize your 
work and writing, sometimes brutally. I’ve been 
fortunate to co-author a manuscript with a phar-
macologist, Dr. Louis Ignarro, destined to win the 
1998 Nobel Prize in Medicine/Physiology for his 
discovery of nitric oxide [47]. (Disclosure: Dr. 
Ignarro did not win his Nobel on the basis of our 
study!) My favorite projects and papers have been 
those that translated basic science observations to 
address and inform important clinicopathologic 
issues – ones that might eventually be used to help 
patients avoid or recover from devastating neuro-
logic illnesses. In 2009, Dr. Michael Sofroniew in 
UCLA’s Dept. of Neurobiology approached me with 
the idea to write a review of basic astrocyte biology 
(his expertise), and how astrocytic dysfunction 
might mediate neurologic disease (my interest) 
[48]. It resulted in my most cited publication and 
led to further productive collaborations that con-
tinue now – studies of astrocyte derangement in 
certain seizure conditions. 
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I benefit daily from my colleagues (Drs. Wil-
liam Yong, Shino Magaki, Negar Khanlou), fellows 
(currently Drs. Zesheng Chen and Josh Byers) and 
technically super-skilled histotechnologists and 
staff research associates (e.g. Kazu Williams, cur-
rent laboratory manager of the Easton Center Brain 
Bank, Nelly Vehabedian, Jennifer Yi, Cecilia Choi). 
Part of the group is shown in Figures 9 and 10, 
masked and ‘social distancing’ (at least in Figure 10) 
as appropriate for the pandemic. When one of the 
technical staff contributes significantly to a re-
search project and the resultant publication, I in-
clude her/him as a co-author on the manuscript. 
Table 2 lists key senior research technicians and lab 
managers who have each co-authored several pub-
lications, many of which have been cited 100+ 
times (per the Web of Science). I take pride that 
many of these skilled technicians have a publication 
record that surpasses (in both quantity and quality) 
those of some junior faculty. Sadly, one of the indi-
viduals on that list (Justine Pomakian) passed earli-
er this year after a long battle with leukemia. An-
other (Spencer Tung) will graduate this year as a 
physician.  
A huge bonus or perk of academic life is the 
possibility to teach, train and influence others – 
including medical students, basic science col-
leagues, graduate students, postdoctoral fellows, 
residents and clinical fellows. I am especially proud 
of the many Neuropathology fellows who have 
graduated from the UCLA training program and 
have gone out to initiate clinical and/or research 
programs of their own. Our goal as teachers and 
mentors should be to foster the creation of 
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Fig 9: Team Neuropathology at UCLA, 2020 (briefly suspending social distancing rules during the COVID 19 epidemic) 
 
individuals who are better than we are – more cre-
ative, more energetic, better and more insightful 
diagnosticians. I flatter myself to think that over-
seas visitors who spent significant time at UCLA 
Neuropathology – Drs. Sung Hye Park from Korea, 
Remco Natte from the Netherlands, Orestes Solis 
from the Philippines, Hajime Miyata from Japan, 
Regina von Einsiedel from Germany, many others – 
brought back to their home countries skills and 
knowledge gained in Los Angeles in UCLA’s labora-
tory of Neuropathology. 
The joy of scientific meetings, sabatti-
cals, visiting professorships and aca-
demic visits 
Academics can be fun, terrific fun! Most of us 
enjoy scientific meetings – well, used to enjoy them 
before they devolved into sitting in front of a com-
puter screen, asking ‘Should I share my screen? 
UNMUTE yourself… Can everyone hear me? Inter-
esting living room décor, or is it an artificial back-
ground? OH NO, black screen again’, etc. I have a 
nagging fear that the trainees of today will come to 
think: This really isn’t so bad! Perhaps it is accepta-
ble as a temporary substitute, but of course there is 
nothing to compare with the give and take of in 
person conferences, the body language and passion 
that are evident in heated or even subdued scien-
tific debates, the stimulating discussions – and yes, 
gossip! – that occur over cocktails and meals. I re-
call an American Association of Neuropathologists 
meeting (in the early days of my career) during 
which two senior prominent academics who both 
worked on neurodegenerative diseases (names 
withheld to protect the guilty… though alas, both 
are now deceased…) almost came to blows in front 
of a poster focusing on the pathogenesis and signif-
icance of senile plaques. A little embarrassing, but 
also somewhat gratifying that each should care so 
completely and enthusiastically about the signifi-
cance of these tiny (though controversial) brain 
lesions – whose importance and relevance to Alz-
heimer’s disease are still debated today. 
What would academic life be without sabbati-
cals? I spent a marvelous year in the early 1990s 
with Dr. Clayton A. Wiley at UC San Diego, learning 
the basics of molecular biology and diagnostics as 
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Fig 10: Team Neuropathology at UCLA, practicing social distancing 
 
applied to human brain specimens, especially those 
originating from corticectomies for intractable sei-
zures [49]. I had the opportunity to work with an 
outstanding technician, Rebecca Wang (who sadly 
died of metastatic melanoma a few years later) and 
Dr. Cris Achim, who remains a friend and collabora-
tor while now on faculty at UCSD. In 1993, I was 
kindly and generously funded by the DAAD (Ger-
man Academic Exchange Service) to work for sev-
eral weeks with Heiko and Eva Braak in Frankfurt – 
learning how elegant neuroanatomic methods that 
they had perfected could provide insights into Alz-
heimer’s disease. 
I’ve had the opportunity to speak and study in 
countries I would probably not have visited, save 
for an invitation to lecture or work there – usually 
at the expense of the host nation/city/academic 
institution, for which generosity I am sincerely 
grateful. I’ve even given a lecture in Riga, Latvia 
(2015) and was interviewed in Latvian (of course I 
speak the language, in fact English is my second 
language) on their national radio network. In 1997 
(for 6 months) and later in 2004 (for a shorter time 
interval), I had the chance to do research and 
teaching as a Visiting Professor (‘Hoogleraar’) at the 
Leiden University Medical Center, located in an 
historic city that is home to an equally ancient and 
revered university – what might be described as a 
college town in the USA. Leiden is situated between 
Amsterdam and den Haag (closer to the latter) in 
the Netherlands and is a short bicycle ride to Kat-
wijk on the North Sea coast. I shared an office, and 
many stimulating discussions (about neuropatholo-
gy, politics, the Dutch royal family and other non-
scientific matters) with Dr. Marion Maat-Schieman 
[Figure 11]. I had the privilege to study, in great 
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detail and with Marion’s assistance and much input 
from Dr. Remco Natte (now a successful 
Pathologist in Holland), the fascinating and unique 
Dutch form of hereditary cerebral amyloid angiopa-
thy that results from a distinctive APP codon 693 
mutation. This causes perhaps the purest form of 
vascular dementia resulting from microvascular 
disease, at least beta-amyloid CAA [50]. Remco 
later spent several productive months performing 
complex tissue culture experiments (using vascular-
derived smooth muscle cells) in my lab at UCLA. In 
1998, Burroughs Wellcome generously provided 
me with funds to work for a month with Dr. Mi-
chael Farrell at the Beaumont Hospital in Dublin. 
For several years in the early 2010s, I had the privi-
lege to travel to Manila in the Philippines to lecture 
at the University of Santo Tomas and several na-
tional and international meetings held in that fasci-
nating country. Manila itself is full of paradoxes – 
great wealth and grinding poverty among them, 
sometimes existing in close physical proximity – 
and is one of the most welcoming and hospitable 
nations in the world. 
 
 
Fig 11: Dr. Marion Maat-Schieman, retired Neuropathologist, 
Leiden University Medical Center, the Netherlands 
 
I am proud to be both Canadian and Ameri-
can, hold two passports and even have a home in 
Vancouver, Canada – which I hope to see again 
some day after the COVID19-related Canadian/USA 
travel restrictions are lifted or at least decreased. 
For several summers from 2013-2017, I spent a 1-2 
week micro-sabbatical in Vancouver, working with 
Dr. Ian Mackenzie and his associates at the Van-
couver Hospital, refining my diagnostic skills in the 
area of frontotemporal dementia and lobar degen-
erations, enjoying this almost impossibly beautiful 
city, and Ian’s amazing knowledge of this complex 
group of disorders. One of the great tragic conse-
quences of COVID 19 is the impact it has had on 
international travel. 
Joining in the life of the university 
UCLA Medical Center (for many years now the 
Ronald Reagan UCLA Medical Center/ RRUMC) is 
located at the southern part of the larger UCLA 
campus. Unlike many metropolitan medical cen-
ters, it is thus closely linked not only to the non-
medical scientific departments with which we in-
teract (including most notably Chemistry and Bio-
chemistry, Biomedical Engineering) but also the 
arts and humanities. While I have been at UCLA, 
two faculty members in the Department of Chemis-
try/Biochemistry (Donald Cram and Paul Boyer) 
have been awarded Nobel Prizes; excellent re-
source to have when one is contemplating experi-
ments with a biochemical component. Since arriv-
ing at UCLA as a junior faculty member, I’ve taken 
advantage of this proximity, having served for sev-
eral years on the campus-wide Graduate Council 
and, more recently, the university’s Council on Ac-
ademic Personnel (CAP). CAP is a committee of 12-
15 senior faculty members representing all (most) 
segments of UCLA, who review the dossiers of oth-
er UCLA academic faculty for initial appointment, 
major academic promotions (e.g. to the rank of 
Distinguished Professor) or appointment to an en-
dowed Chair. Serving on CAP provided a remarka-
ble overview of the diversity of talent and skills at 
the university. It also gave an interesting perspec-
tive into the heterogeneous activities that qualify 
as creative accomplishment in UCLA Departments 
such as Near Eastern Languages and Culture, Eng-
lish, Philosophy and Digital Media, to name four 
among many. 
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Life does not end with retirement – 
nor should it… and closing comments 
I formally retired from my full time equivalent 
(FTE) in July 2016, and have been on ‘recall’ for 
clinical and academic work since then, continuing 
to the present time. For some unknown reason, 
UCLA allows recall faculty to work 43% of time 
(??!!), though I probably spend more time than that 
in my office and lab. In 2017, I was honored by the 
British Neuropathological Society with the Alfred 
Meyer Medal and Lectureship, received and deliv-
ered in London; the British surely are the masters 
at doing this sort of festive event, and I was suitably 
‘chuffed’ and grateful for the honor. That same 
year I received the award for Meritorious Contribu-
tions to Neuropathology, from the American Asso-
ciation of Neuropathologists. Agreed – awards are 
not that important, but they are a lovely symbol of 
regard from one’s colleagues. Over many years, I 
have established the Gunnar Vinters bursary at 
Lakehead University in my home town of Thunder 
Bay. Last year, I also endowed the Elize and Arnold 
Vinters scholarship, in memory of my grandparents, 
at the Northern Ontario Medical School in the same 
university. I enjoy building on the endowment for 
each academic award, annually and encouraging 
others to contribute. 
Since 2018 I have been doing locum work at 
the University of Alberta, in a unit known as Alberta 
Precision Laboratories (APL). My wonderful col-
leagues there are Drs. Laura Schmitt, Frank van 
Landeghem and Sumit Das [Figure 12]. The work is 
currently on hiatus (since February, 2020), pending 
resumption of travel between Canada and the USA, 
but I hope that happens soon. I recently co-
authored my first paper with colleagues at APL 
[51]. It is a form of coming full circle, since I in-




Fig 12: My Neuropathology colleagues at Alberta Precision Laboratories, Edmonton, Alberta, 2020 (L to R Drs. Laura Schmitt, Frank van 
Landeghem, Sumit Das) 
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I love travel, including (and especially) air 
travel… but as of this writing have not been on an 
airplane or near an airport for 5+ months. Howev-
er, there is much still to do at UCLA, projects that – 
so I hope – benefit from my input, complex cases 
on which I can shed some light. In my spare time, I 
revel in the delights of Venice Beach, California, 
where there is – shall we say – never a dull mo-
ment. It is a beachside region of Los Angeles 
founded in the early 1900s by Abbot Kinney, a to-
bacco heir who was so impressed with Venice, Italy, 
that he thought it would be fun to replicate it in 
southern California. I have great friends there, 
throughout L.A. and in Canada and five accom-
plished Godchildren whose antics keep life interest-
ing. In my spare time, which seems sometimes not 
to be terribly abundant, I write short stories and 
OPED pieces, none of which is destined for publica-
tion, though I’ve published a few ‘back in the day’. 
Now it is time to end this reflection, which 
seems to have expanded to the length of a novella! 
When I was in medical school, I never dreamed I 
would spend most of my adult life in southern Cali-
fornia. As I heard or read somewhere, ‘Life is what 
happens to you while you are making plans…’ – 
how true. I appreciate Free Neuropathology giving 
me the opportunity to write this piece.  
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